CervoMed (NasdaqCM:CRVO) Conference October 22, 2025 11:25 AM ET Company ParticipantsMatt Wenton - Chief Commercial and Business OfficerModeratorWelcome back, everyone. We have CervoMed Inc. they trade on the Nasdaq under the symbol CRBO. It's a clinical-stage company focused on developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38 MAP kinase alpha. Please welcome Chief Commercial and Business Officer Matt Wenton. Matt, sorry for mispronouncing all ...

BOSTON, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present at the Emerging Growth Conference, being held virtually on Wednesday, October 22, 2025. Presentation DetailsFormat: Corporate PresentationDate: Wednesday, October 22, 2025Time: 11:25 – 11:55 AM ETWebcast Link: https://goto ...

CervoMed Inc. (NASDAQ:CRVO) on Wednesday shared additional data from its Phase 2b RewinD-LB trial of neflamapimod for dementia with Lewy bodies (DLB).The results are based on the final analyses of the RewinD-LB trial, conducted after the August 2025 database lock for the full 48-week trial (16 weeks placebo-controlled (Initial Phase), followed by a 32-week neflamapimod-only extension (Extension Phase)).In the subset of participants whose plasma ptau181 levels were below 21 pg/mL at screening, results includ ...

Significant improvement relative to placebo on primary outcome measure, change in Clinical Dementia Rating Sum of Boxes (CDR-SB), demonstrated in a within-subject analysis in participants with low likelihood of having Alzheimer’s disease (AD) co-pathology Significant reduction in plasma levels of a well-established biomarker of neurodegeneration, plasma glial fibrillary acidic protein (GFAP), correlated to treatment response assessed by CDR-SB CervoMed anticipates U.S. Food and Drug Administration (FDA) fee ...

Expanding executive leadership team to prepare for late-stage development, strategic organizational growth, and market readinessBOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced the appointment of Matthew Winton, Ph.D., as Chief Commercial and Business Officer. Dr. Winton joins CervoMed with nearly two decades of experience in the global biotechnolog ...

BOSTON, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 4th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Thursday, October 9, 2025. Panel DetailsTitle: “Small Firms Tackling Blockbuster Indications”Date: Thursday, October ...

BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that the promising development program and potential benefits of neflamapimod for the treatment of Dementia with Lewy Bodies (DLB) were highlighted in a presentation on advances in DLB drug development by Dr. James Galvin at the 150th Annual American Neurological Association (ANA) conference held Sep ...

Reported 32-week data from Phase 2b RewinD-LB Trial Extension phase showing neflamapimod treatment resulted in a substantial reduction in clinically significant worsening compared to control arm over 32 weeks, which improved further among patients who have minimal evidence of Alzheimer's disease (AD) co-pathology (ptau181 < 2.2 pg/mL at screening) At week 32 of the Extension phase, patients treated with neflamapimod demonstrated a significant reduction from baseline in plasma levels of glial fibrillary acid ...

BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company management will participate in a fireside chat and one-on-one investor meetings at the CG 45 Annual Growth Conference being held in Boston, MA, on Tuesday, August 12 to Thursday, August 14, 2025. Investor Contact: PJ Kelleher LifeSci Advisors Investors@cervomed.com 617-430-7579 The webcast of the fireside chat wil ...

临床试验数据 - 公司公布口服药物neflamapimod治疗路易体痴呆(DLB)的2b期RewinD-LB试验32周扩展阶段数据 初始16周双盲安慰剂对照阶段纳入159名患者 扩展阶段所有患者接受40mg每日三次给药[1] - 扩展阶段数据显示药物持续减缓疾病进展 并显著降低神经退行性病变关键血浆标志物水平[2] - 新胶囊组患者疾病进展速度显著慢于旧胶囊组 且在ptau181<2.2 pg/mL亚组中观察到更大风险降低[6] 生物标志物表现 - 扩展阶段32周时 新胶囊组患者神经胶质纤维酸性蛋白(GFAP)血浆水平较基线显著降低 全体患者平均下降18.4±4.0 pg/mL ptau181<2.2 pg/mL亚组下降21.2±4.4 pg/mL[6] - 安慰剂组在双盲阶段16周时GFAP水平平均上升1.1±3.0 pg/mL(全体)和1.1±3.3 pg/mL(ptau181<2.2亚组)[6] - 研究同时评估ptau181不同截断值水平 分析其与阿尔茨海默病生物标志物ptau217的相关性[6] 药物安全性 - 新旧胶囊耐受性特征相当 扩展阶段未发现新的安全性信号[5] - 新胶囊组在ptau181<2.2 pg/mL患者中跌倒发生率显著低于旧胶囊组(p=0.025)和安慰剂组(p=0.007)[5] 市场反应 - 公司股价单日上涨29.4%至11.62美元[6]